Department of Clinical Oral Oncology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan;
Department of Clinical Oral Oncology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Anticancer Res. 2021 Nov;41(11):5785-5791. doi: 10.21873/anticanres.15395.
BACKGROUND/AIM: This study was conducted to compare the efficacy and safety of the weekly cetuximab plus paclitaxel (wCmab-PTX) regimen with those of the EXTREME regimen in patients with recurrent or metastatic oral squamous cell carcinoma (R/M OSCC).
This multicenter retrospective study involved a chart review of the clinical records of R/M OSCC patients treated with wCmab-PTX in each institution between January 2013 and December 2017. Data were collected, and the efficacy, safety, and treatment outcomes were analyzed.
The best overall response and disease control rates were 48.4% and 61.3%, respectively. The median PFS and OS were 6 and 13 months, respectively. There was no significant difference in prognosis with or without previous platinum administration. The grade 3-4 adverse events were leukopenia (16.1%), followed by acne-like rash (12.9%), and neutropenia (9.7%). All adverse events, excluding more than grade 3 infusion reactions, were tolerable and manageable.
wCmab-PTX may be considered as a treatment option for R/M patients with OSCC that is refractory to platinum-based chemotherapy, or progressive disease after receiving chemotherapy.
背景/目的：本研究旨在比较每周西妥昔单抗联合紫杉醇（wCmab-PTX）方案与 EXTREME 方案治疗复发性或转移性口腔鳞状细胞癌（R/M OSCC）患者的疗效和安全性。
这是一项多中心回顾性研究，对 2013 年 1 月至 2017 年 12 月期间各机构接受 wCmab-PTX 治疗的 R/M OSCC 患者的临床记录进行了图表回顾。收集了数据，并分析了疗效、安全性和治疗结果。
最佳总缓解率和疾病控制率分别为 48.4%和 61.3%。中位无进展生存期和总生存期分别为 6 个月和 13 个月。是否有铂类药物治疗史对预后无显著影响。3-4 级不良事件为白细胞减少症（16.1%），其次为痤疮样皮疹（12.9%）和中性粒细胞减少症（9.7%）。除 3 级以上输液反应外，所有不良事件均可耐受和管理。
wCmab-PTX 可作为铂类化疗耐药或化疗后进展的 R/M OSCC 患者的治疗选择。
